Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Crysalin appoints Brister as chairman

This article was originally published in Scrip

Executive Summary

Crysalin, a UK protein structure determination company spun out of the University of Oxford in 2007, has appointed David Brister as chairman. He has more than 20 years' experience in private equity and venture capital, most notably at 3i and MVM. He was an investor in Cambridge Antibody Technology, Acambis and Oxford GlycoSciences and was chairman of Domantis for five years from its inception. He has also held the role of chief business officer at Evotec.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts